Faculty profile

Stanley Liu

Back to faculty

Associate ProfessorDepartment of Radiation OncologyUniversity of Toronto

Stanley Liu

Associate Professor

Department of Radiation Oncology

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Scholar ORCID

Supervision signals

Professors usually supervise graduate students in their department's programs.
14 publications in the last five years, latest in 2026.
Principal investigator on 2 research grants (2 CIHR), most recently in 2023.
Supervised 1 trainee who won CIHR awards, most recently in 2019.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Education

Profiles and links

University Profile Personal Website Google Scholar iDORCID

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Cancer Clinical oncology

Latest papers

Bowel Bag Dosimetric Parameters for Ultrahypofractionated Pelvic Elective Nodal Irradiation in Prostate Cancer.
International journal of radiation oncology, biology, physics · 2026
SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer.
JAMA network open · 2026
Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective Trials.
European urology oncology · 2025

All 35 publications

Latest funding

Primary prostate cancer cells as novel models for patient therapy prediction
CIHR · 2023 · Nominated PI
$883,576
'Two-Step Authentication' for Optimal Prostate Cancer Risk Determination: An "Extracellular Vesicle"-Based Liquid Biopsy Followed by Multi-Parametric MRI.
CIHR · 2022 · Co-investigator
$1,637,100
Conditionally-Reprogrammed Primary Prostate Cancer Cells as Novel Models for Patient Therapy Prediction
CIHR · 2019 · Supervisor
$105,000

All 5 grants and awards

35 publications.

Bowel Bag Dosimetric Parameters for Ultrahypofractionated Pelvic Elective Nodal Irradiation in Prostate Cancer.

Ong WL, Davidson M, Wronski M, Kang T, Cheung P, Chu W, Chung H, Liu S, Morton G, Tseng CL, Vesprini D, Zhang L, Poon C, Loblaw A

International journal of radiation oncology, biology, physics2026

DOI: 10.1016/j.ijrobp.2025.08.014 PMID: 40819809

SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer.

Udovicich C, Cheung P, Chu W, Chung H, Detsky J, Liu S, Morton G, Tseng CL, Vesprini D, Hudson JM, Ong WL, Kennedy T, Helou J, Davidson M, Ravi A, McGuffin M, Zhang L, Mamedov A, Deabreu A, Kulasingham-Poon M, Loblaw A

JAMA network open2026

DOI: 10.1001/jamanetworkopen.2026.0146 PMID: 41739470

Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective Trials.

Udovicich C, Cheung P, Chu W, Chung H, Detsky J, Liu S, Morton G, Szumacher E, Tseng CL, Vesprini D, Ong WL, Kennedy T, Davidson M, Ravi A, McGuffin M, Zhang L, Mamedov A, Deabreu A, Kulasingham-Poon M, Loblaw A

European urology oncology2025

DOI: 10.1016/j.euo.2024.12.015 PMID: 39904690

Screening guidelines for individuals at increased risk for prostate cancer.

Lorentz J, Woollcombe J, Loblaw A, Liu S, Vesprini D

Canadian Urological Association journal = Journal de l'Association des urologues du Canada2024

DOI: 10.5489/cuaj.8710 PMID: 38896481

Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year update.

Hudson JM, Loblaw A, McGuffin M, Chung HT, Tseng CL, Helou J, Cheung P, Szumacher E, Liu S, Zhang L, Deabreu A, Mamedov A, Morton G

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2024

DOI: 10.1016/j.radonc.2024.110381 PMID: 38879130

Urethra contouring on computed tomography urethrogram versus magnetic resonance imaging for stereotactic body radiotherapy in prostate cancer.

Ong WL, Allan Hupman M, Davidson M, Ruschin M, Detsky J, Liu S, Vesprini D, Loblaw A

Clinical and translational radiation oncology2024

DOI: 10.1016/j.ctro.2023.100722 PMID: 38234697

Ultrasound-stimulated microbubbles enhanced vascular disruption in fractionated radiotherapy-treated tumours via ASMase activation.

Leong KX, Yang W, Sharma D, Liu S, Czarnota GJ

Disease models & mechanisms2023

DOI: 10.1242/dmm.049531 PMID: 37278613

To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate Cancer.

Ong WL, Cheung P, Chung H, Chu W, Detsky J, Liu S, Morton G, Szumacher E, Tseng CL, Vesprini D, Davidson M, Ravi A, McGuffin M, Zhang L, Mamedov A, Deabreu A, Kulasingham-Poon M, Loblaw A

International journal of radiation oncology, biology, physics2023

DOI: 10.1016/j.ijrobp.2023.06.250 PMID: 37419394

Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancer.

Ong WL, Davidson M, Cheung P, Chung H, Chu W, Detsky J, Liu S, Morton G, Szumacher E, Tseng CL, Vesprini D, Ravi A, McGuffin M, Zhang L, Mamedov A, Deabreu A, Kulasingham-Poon M, Loblaw A

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2023

DOI: 10.1016/j.radonc.2023.109864 PMID: 37619656

Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trial.

Ong WL, Cheung P, Chung H, Chu W, Detsky J, Liu S, Morton G, Szumacher E, Tseng CL, Vesprini D, Davidson M, Ravi A, McGuffin M, Zhang L, Mamedov A, Deabreu A, Kulasingham-Poon M, Loblaw A

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2023

DOI: 10.1016/j.radonc.2023.109503 PMID: 36754232

Profile data last refreshed on September 25, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

Stanley Liu

Research

Latest papers

Latest funding

Bowel Bag Dosimetric Parameters for Ultrahypofractionated Pelvic Elective Nodal Irradiation in Prostate Cancer.

SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer.

Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective Trials.

Screening guidelines for individuals at increased risk for prostate cancer.

Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year update.

Urethra contouring on computed tomography urethrogram versus magnetic resonance imaging for stereotactic body radiotherapy in prostate cancer.

Ultrasound-stimulated microbubbles enhanced vascular disruption in fractionated radiotherapy-treated tumours via ASMase activation.

To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate Cancer.

Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancer.

Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trial.

Primary prostate cancer cells as novel models for patient therapy prediction

'Two-Step Authentication' for Optimal Prostate Cancer Risk Determination: An "Extracellular Vesicle"-Based Liquid Biopsy Followed by Multi-Parametric MRI.

Conditionally-Reprogrammed Primary Prostate Cancer Cells as Novel Models for Patient Therapy Prediction

Non-invasive multi-omics urinary biomarkers to guide prostate cancer management

Ultrasound-Stimulated Microbubble Enhancement of Tumour Radiation Response

Frequent collaborators

Andrew Loblaw

Gerard Morton

Ewa Szumacher

Theos Tsakiridis

Gregory Steinberg

Nicole Mittmann

Alice Dragomir

Maureen Trudeau

Danny Enepekides

Bharati Bapat

Lisa Di Prospero

Tobias Berg

Justin Lee

Thomas Farrell

Jianhan Wu

Colin Collins

Philip Awadalla

Trevor Pugh

Jonathan Bramson

Katherine Zukotynski

Stanley Liu

Research

Latest papers

Latest funding

Bowel Bag Dosimetric Parameters for Ultrahypofractionated Pelvic Elective Nodal Irradiation in Prostate Cancer.

SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer.

Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective Trials.

Screening guidelines for individuals at increased risk for prostate cancer.

Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19&#xa0;Gy or two fractions of 13.5&#xa0;Gy: A 9-year update.

Urethra contouring on computed tomography urethrogram versus magnetic resonance imaging for stereotactic body radiotherapy in prostate cancer.

Ultrasound-stimulated microbubbles enhanced vascular disruption in fractionated radiotherapy-treated tumours via ASMase activation.

To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate Cancer.

Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancer.

Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trial.

Primary prostate cancer cells as novel models for patient therapy prediction

'Two-Step Authentication' for Optimal Prostate Cancer Risk Determination: An "Extracellular Vesicle"-Based Liquid Biopsy Followed by Multi-Parametric MRI.

Conditionally-Reprogrammed Primary Prostate Cancer Cells as Novel Models for Patient Therapy Prediction

Non-invasive multi-omics urinary biomarkers to guide prostate cancer management

Ultrasound-Stimulated Microbubble Enhancement of Tumour Radiation Response

Frequent collaborators

Andrew Loblaw

Gerard Morton

Ewa Szumacher

Theos Tsakiridis

Gregory Steinberg

Nicole Mittmann

Alice Dragomir

Maureen Trudeau

Danny Enepekides

Bharati Bapat

Lisa Di Prospero

Tobias Berg

Justin Lee

Thomas Farrell

Jianhan Wu

Colin Collins

Philip Awadalla

Trevor Pugh

Jonathan Bramson

Katherine Zukotynski

Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year update.